Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Nov 27;33 Suppl 4(0 4):D46-54.
doi: 10.1016/j.vaccine.2015.06.073. Epub 2015 Oct 1.

Enhancing vaccine safety capacity globally: A lifecycle perspective

Robert T Chen  1 , Tom T Shimabukuro  2 , David B Martin  3 , Patrick L F Zuber  4 , Daniel M Weibel  5 , Miriam Sturkenboom  5
Affiliations
Review

Enhancing vaccine safety capacity globally: A lifecycle perspective

Robert T Chen et al. Vaccine. .

Abstract

Major vaccine safety controversies have arisen in several countries beginning in the last decades of 20th century. Such periodic vaccine safety controversies are unlikely to go away in the near future as more national immunization programs mature with near elimination of target vaccine-preventable diseases that result in relative greater prominence of adverse events following immunizations, both true reactions and temporally coincidental events. There are several ways in which vaccine safety capacity can be improved to potentially mitigate the impact of future vaccine safety controversies. This paper aims to take a "lifecycle" approach, examining some potential pre- and post-licensure opportunities to improve vaccine safety, in both developed (specifically U.S. and Europe) and low- and middle-income countries.

Keywords: AEFI; Capacity building; LMICs; Sustainability; Vaccine safety.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: MS is leading a research group that occasionally conducts research for pharmaceutical companies including Boeheringer, Pfizer, Novartis, Eli Lilly. These are not related to this paper and grants all arrive at Erasmus University Medical Center. None for the other co-authors.

Figures

Figure 1
Figure 1
Potential stages in the evolution of immunization program, showing the dynamics of the interaction between vaccine coverage, disease incidence and vaccine adverse events, as the program matures from pre-vaccine to disease eradication.(14)
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Moxon ER, Das P, Greenwood B, Heymann DL, Horton R, Levine OS, et al. A call to action for the new decade of vaccines. Lancet. 2011;378(9788):298–302. - PubMed
    1. Zipprich J, Winter K, Hacker J, Xia D, Watt J, Harriman K. Measles outbreak - California, December 2014-February 2015. MMWR Morbidity and mortality weekly report. 2015;64(6):153–4. - PMC - PubMed
    1. Wakefield AJ, Murch SH, Anthony A, Linnell J, Casson DM, Malik M, et al. Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet. 1998;351(9103):637–41. - PubMed
    1. Retraction--Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet. 2010;375(9713):445. - PubMed
    1. Taylor LE, Swerdfeger AL, Eslick GD. Vaccines are not associated with autism: an evidence-based meta-analysis of case-control and cohort studies. Vaccine. 2014;32(29):3623–9. - PubMed